

ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Sileo 0.1 mg/ml oromucosal gel for dogs

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each ml of the oromucosal gel contains:

Active substance:

0.1 mg dexmedetomidine hydrochloride equivalent to 0.09 mg dexmedetomidine.

Excipients:

Qualitative composition of excipients and other constituents
Water, purified
Propylene glycol
Hydroxypropylcellulose
Sodium lauryl sulfate
Brilliant blue (E133)
Tartrazine (E102)
Sodium hydroxide (for pH adjustment)
Hydrochloric acid (for pH adjustment)

Translucent, green gel.

3. CLINICAL INFORMATION

3.1 Target species

Dogs.

3.2 Indications for use for each target species

Alleviation of acute anxiety and fear associated with noise in dogs.

3.3 Contraindications

Do not use in dogs with severe cardiovascular disorders.

Do not use in dogs with severe systemic disease (graded as ASA III-IV) e.g. end stage renal or liver failure.

Do not use in cases of hypersensitivity to the active substance or to any of the excipients.

Do not use in dogs obviously sedated from previous dosing.

3.4 Special warnings

None.

3.5 Special precautions for use

Special precautions for safe use in the target species:

If the oromucosal gel is swallowed it will become ineffective. Therefore, feeding the dog or giving it treats within 15 minutes after administration of the gel should be avoided. In case the gel is swallowed the dog can be given another dose if necessary 2 hours after the previous dose.

In extremely nervous, excited or agitated animals, the levels of endogenous catecholamines are often high. The pharmacological response elicited by alpha-2 agonists (e.g. dexmedetomidine) in such animals may be reduced.

The safety of administering dexmedetomidine to puppies younger than 16 weeks and dogs over 17 years of age has not been studied.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

In case of accidental ingestion or prolonged mucosal contact, seek medical advice immediately and show the package leaflet or the label to the physician. Do not drive as sedation and changes in blood pressure may occur.

Avoid skin, eye or mucosal contact. Wear impermeable disposable gloves when handling the veterinary medicinal product.

In case of accidental spillage onto skin, wash the exposed skin immediately after exposure with large amounts of water and remove contaminated clothes. In case of eye or oromucosal contact, rinse abundantly with fresh water. If symptoms occur, seek the advice of a physician.

People with known hypersensitivity to dexmedetomidine or any of the excipients should avoid contact with the veterinary medicinal product.

Pregnant women should avoid contact with the veterinary medicinal product. Uterine contractions and decreased foetal blood pressure may occur after systemic exposure to dexmedetomidine.

Advice to the physician:

Dexmedetomidine, the active substance of Sileo is an alpha-2 adrenoceptor agonist. Symptoms after absorption may involve clinical effects including dose-dependent sedation, respiratory depression, bradycardia, hypotension, a dry mouth, and hyperglycaemia. Ventricular arrhythmias have also been reported. Since effects are dose dependent, they are more pronounced in small children than adults. Respiratory and haemodynamic symptoms should be treated symptomatically. The specific alpha-2 adrenoceptor antagonist, atipamezole, which is approved for use in animals, has been used in humans but only experimentally to antagonize dexmedetomidine-induced effects.

Special precautions for the protection of the environment:

Not applicable.

3.6 Adverse events

Dogs:

Common (1 to 10 animals / 100 animals treated):	Emesis Sedation Urinary incontinence Pale mucous membrane ¹
Uncommon (1 to 10 animals / 1 000 animals treated):	Anxiety Gastroenteritis Periorbital oedema Drowsiness

¹Transient, observed at the application site due to peripheral vasoconstriction.

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system. See the package leaflet for respective contact details.

3.7 Use during pregnancy, lactation or lay

The safety of the veterinary medicinal product has not been established during pregnancy and lactation.

Pregnancy and lactation:

The use is not recommended during pregnancy and lactation.


3.8 Interaction with other medicinal products and other forms of interaction

The use of other central nervous system depressants is expected to potentiate the effects of dexmedetomidine and therefore an appropriate dose adjustment should be made.

3.9 Administration routes and dosage

Oromucosal use.

The veterinary medicinal product should be administered onto the oral mucosa between dog's cheek and gum at a dose of 125 micrograms/m². The Sileo oral syringe is capable of delivering the veterinary medicinal product in 0.25 ml increments. Each increment is shown as one dot on the plunger. The dosing table provides the number of dots to be administered corresponding to the dog's bodyweight.



The following dosing table provides the dose volume (in dots) to be administered for the corresponding bodyweight. If the dose for the dog is more than 6 dots (1.5 ml), half of the dose should be administered to the oral mucosa on one side of the dog's mouth and the other half of the dose onto the other side. Do not exceed the recommended dose.

Bodyweight of dog (kg)	Number of dots
2.0–5.5	1 •

5.6–12	2	●●
12.1–20	3	●●●
20.1–29	4	●●●●
29.1–39	5	●●●●●
39.1–50	6	●●●●●●
50.1–62.5	7	●●●●●●●
62.6–75.5	8	●●●●●●●●
75.6–89	9	●●●●●●●●●
89.1–100	10	●●●●●●●●●●

The first dose should be given as soon as the dog shows the first signs of anxiety, or when the owner detects a typical stimulus (e.g. sound of fireworks or thunder) for eliciting anxiety or fear in the respective dog. Typical signs of anxiety and fear are panting, trembling, pacing (frequent change of place, running around, restlessness), seeking people (clinging, hiding behind, pawing, following), hiding (under furniture, in dark rooms), trying to escape, freezing (absence of movements), refusing to eat food or treats, inappropriate urination, inappropriate defecation, salivation, etc. If the fear eliciting event continues and the dog shows signs of anxiety and fear again, re-dosing can be done when 2 hours have passed from the previous dose. The veterinary medicinal product can be dosed up to 5 times during each event.

Instructions for dosing the gel:


Dosing should be performed by an adult.

PREPARATIONS FOR DOSING:



1. WEAR GLOVES


Wear impermeable disposable gloves when handling the veterinary medicinal product and handling the oral syringe.



2. HOLD PLUNGER






Hold the oral syringe plunger so that you can see the dot markings.

DOSE SELECTION AND DOSING:



3. ROTATE RING

Hold the plunger and rotate the ring towards the barrel to select the dose your veterinarian has prescribed to your dog. **Do not pull the plunger!**



4. SET THE DOSE

Position the dosing ring so that the side nearest the barrel is in line with the graduation mark (black line), and the required number of dots shows between the dosing ring and the barrel.

5. CONFIRM THE DOSE

Make sure that you count the dots from the correct part of the plunger (shown in yellow) and that the ring is in line with the graduation mark (shown with the yellow arrow).

6. FOLLOWING DOSES

To administer following doses from the same syringe: Repeat the previous “4. Set the dose” and “5. Confirm the dose” parts of the instructions.

7. PULL CAP (TIGHT)


Pull the cap strongly while holding the barrel. **Note** the cap is very tight (pull, do not twist). Save the cap for replacement.

8. DOSE INTO CHEEK

Place the oral syringe tip between the dog’s cheek and gum and press the plunger until the dosing ring causes the plunger to stop.

9. NOT SWALLOWED

IMPORTANT: The gel should not be swallowed. If the gel is swallowed, it may not be effective.



10. BACK TO PACKAGE

Recap the oral syringe and return it to the outer package as the veterinary medicinal product is sensitive to light. Make sure that the carton is closed properly. Keep the package out of sight and reach of children at all times. Remove and discard gloves.

3.10 Symptoms of overdose (and where applicable, emergency procedures and antidotes)

Signs of sedation may occur when the dose is exceeded. The level and duration of sedation is dose dependent. If sedation occurs, the dog should be kept warm.

Reduced heart rate may be seen after administration of higher than recommended doses of Sileo gel. Blood pressure decreases slightly below normal levels. Respiration rate can occasionally decrease. Higher than recommended doses of Sileo gel may also induce a number of other alpha-2 adrenoceptor mediated effects, which include mydriasis, depression of motor and secretory functions of the gastrointestinal tract, temporary AV-blocks, diuresis and hyperglycaemia. A slight decrease in body temperature may be observed.

The effects of dexmedetomidine can be eliminated using a specific antidote, atipamezole (alpha-2 adrenoceptor antagonist). In case of overdose, the appropriate dose of atipamezole calculated in micrograms is 3 times (3X) the dose of administered dexmedetomidine hydrochloride in Sileo gel. Atipamezole (at the concentration of 5 mg/ml) dose in millilitres is one sixteenth (1/16th) of the dose volume of Sileo gel.

3.11 Special restrictions for use and special conditions for use, including restrictions on the use of antimicrobial and antiparasitic veterinary medicinal products in order to limit the risk of development of resistance

Not applicable.

3.12 Withdrawal periods

Not applicable.

4. PHARMACOLOGICAL INFORMATION

4.1 ATCvet code: QN05CM18

4.2 Pharmacodynamics

Sileo contains dexmedetomidine (as the hydrochloride salt) as the active substance. Dexmedetomidine is a potent and selective alpha-2 adrenoceptor agonist that inhibits the release of noradrenaline (NA) from noradrenergic neurons, blocks the startle reflex and thus counteracts arousal.

Dexmedetomidine as an alpha-2 adrenoceptor agonist alters the levels of NA, serotonin (5-HT) and dopamine (DA) in the hippocampus and frontal cortex, indicating that such compounds affect also the regions of the brain involved in creating and maintaining complex anxieties. In rodents alpha-2 adrenoceptor agonists reduce synthesis of NA, DA, 5-HT and the 5-HT precursor, 5-HTP (5-hydroxytryptophan), in the frontal cortex, hippocampus, striatum and hypothalamus and as a result decreases motor behaviour and signalling associated with distress.

In summary, dexmedetomidine, by decreasing central noradrenergic and serotonergic neurotransmission, is effective in alleviating canine acute anxiety and fear associated with noise. In

addition to anxiolytic effect, dexmedetomidine has other well-known dose dependent pharmacological effects such as lowering of heart rate and rectal temperature, and peripheral vasoconstriction. These and other effects are described in more detail in section 3.10 on overdose.

4.3 Pharmacokinetics

Oral bioavailability of dexmedetomidine is poor due to extensive first-pass metabolism. No measurable concentrations were found after gastro-intestinal gavage of dexmedetomidine to dogs. When administered via the oral mucosa, enhanced bioavailability is observed as a result of absorption in the oral cavity and the avoidance of first-pass metabolism in the liver.

The maximum concentration of dexmedetomidine occurs at about 0.6 hours after intramuscular or oromucosal administration. In a pharmacokinetic study in dogs the oromucosal mean bioavailability of dexmedetomidine was 28 %. The apparent volume of distribution of dexmedetomidine in dogs is 0.9 l/kg. In the circulation, dexmedetomidine is largely bound to plasma proteins (93 %). When studied in rats, the distribution of dexmedetomidine into rat tissues was rapid and wide with concentrations higher than in plasma for many tissues. Its levels in the brain were from 3-fold to 6-fold higher than the levels in plasma.

Dexmedetomidine is eliminated by biotransformation mainly in the liver, with a half-life in dogs ranging from 0.5 to 3 hours after oromucosal administration. Metabolism accounts for more than 98 % of the elimination. Known metabolites show no or negligible activity. The major metabolic routes in dogs are hydroxylation of a methyl substituent and further oxidation to a carboxylic acid or O-glucuronidation of the hydroxylated product. N-methylation, N-glucuronidation and oxidation in the imidazole ring have also been observed. Metabolites are excreted mainly in the urine with a minor fraction found in the faeces.

5. PHARMACEUTICAL PARTICULARS

5.1 Major incompatibilities

Not applicable.

5.2 Shelf life

Shelf life of the veterinary medicinal product as packaged for sale: 3 years.

Shelf life after first opening the immediate packaging (removal of the cap): 4 weeks.

5.3 Special precautions for storage

Keep the oral syringe in the outer carton in order to protect from light.

5.4 Nature and composition of immediate packaging

Pre-filled 3 ml HDPE oral syringes with graduations from 0.25 ml (1 dot) to 3 ml (12 dots). The oral syringe is fitted with a plunger, dosing ring and end cap (for sealing it).

Each oral syringe is packed in an individual child-resistant carton.

Pack sizes:

- Single pack of 1 oral syringe.
- Multipacks of 3 (3 packs of one), 5 (5 packs of one), 10 (10 packs of one) and 20 (20 packs of one) oral syringes.

Multipacks of 5, 10 and 20 oral syringes are intended to be supplied only to veterinarians.

Not all pack sizes may be marketed.

5.5 Special precautions for the disposal of unused veterinary medicinal products or waste materials derived from the use of such products

Medicines should not be disposed of via wastewater or household waste.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any national collection systems applicable to the veterinary medicinal product concerned.

6. NAME OF THE MARKETING AUTHORISATION HOLDER

Orion Corporation

7. MARKETING AUTHORISATION NUMBER(S)

EU/2/15/181/001-005

8. DATE OF FIRST AUTHORISATION

Date of first authorisation: 10/06/2015

9. DATE OF THE LAST REVISION OF THE SUMMARY OF THE PRODUCT CHARACTERISTICS

{DD/MM/YYYY}

10. CLASSIFICATION OF VETERINARY MEDICINAL PRODUCTS

Veterinary medicinal product subject to prescription.

Detailed information on this veterinary medicinal product is available in the [Union Product Database \(https://medicines.health.europa.eu/veterinary\)](https://medicines.health.europa.eu/veterinary).

ANNEX II

OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION

None.

ANNEX III
LABELLING AND PACKAGE LEAFLET

A. LABELLING

PARTICULARS TO APPEAR ON THE OUTER PACKAGE

CARTON (1 pre-filled syringe)

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Sileo 0.1 mg/ml oromucosal gel

2. STATEMENT OF ACTIVE SUBSTANCES

1 ml: Dexmedetomidine hydrochloride 0.1 mg

3. PACKAGE SIZE

1 x 3 ml oral syringe

4. TARGET SPECIES



5. INDICATIONS

6. ROUTES OF ADMINISTRATION

Oromucosal use.

7. WITHDRAWAL PERIODS

8. EXPIRY DATE

Exp. {mm/yyyy}
Once opened use within 4 weeks.
Once opened use by...

9. SPECIAL STORAGE PRECAUTIONS

Keep the oral syringe in the outer carton in order to protect from light.

10. THE WORDS “READ THE PACKAGE LEAFLET BEFORE USE”

Read the package leaflet before use.

11. THE WORDS “FOR ANIMAL TREATMENT ONLY”

For animal treatment only.

12. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”

Keep out of the sight and reach of children.

13. NAME OF THE MARKETING AUTHORISATION HOLDER

Orion Corporation

14. MARKETING AUTHORISATION NUMBERS

EU/2/15/181/001 (1 x 3 ml oral syringe)


15. BATCH NUMBER

Lot {number}


QR code to be included + <https://www.sileodosing.com>

Instructions for opening the package:

1.



2.



1. Push to break the seals.
2. Push the button and pull to open.

Text on the seals:

Push

Pull

On the inner part of the carton:

Make sure that the package is closed correctly so that it remains child-resistant. When closing, the Sileo logo must be on the same side on both the inner and the outer carton so that the yellow button becomes visible.

PARTICULARS TO APPEAR ON THE OUTER PACKAGE

CARTON (3 x 1, 5 x 1, 10 x 1 and 20 x 1 pre-filled syringes)

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Sileo 0.1 mg/ml oromucosal gel

2. STATEMENT OF ACTIVE SUBSTANCES

1 ml: Dexmedetomidine hydrochloride 0.1 mg

3. PACKAGE SIZE

3 packs of (3 ml) oral syringes
5 packs of (3 ml) oral syringes
10 packs of (3 ml) oral syringes
20 packs of (3 ml) oral syringes

This multipack is not intended to be supplied directly to the animal owner.
(for 5 x 1, 10 x 1 and 20 x 1 multipacks only)

4. TARGET SPECIES



5. INDICATIONS

6. ROUTES OF ADMINISTRATION

Oromucosal use.

7. WITHDRAWAL PERIODS

8. EXPIRY DATE

Exp. {mm/yyyy}

9. SPECIAL STORAGE PRECAUTIONS

Keep the oral syringe in the outer carton in order to protect from light.

10. THE WORDS “READ THE PACKAGE LEAFLET BEFORE USE”

Read the package leaflet before use.

11. THE WORDS “FOR ANIMAL TREATMENT ONLY”

For animal treatment only.

12. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”

Keep out of the sight and reach of children.

13. NAME OF THE MARKETING AUTHORISATION HOLDER

Orion Corporation

14. MARKETING AUTHORISATION NUMBERS

EU/2/15/181/002 (3 (1 x 3 ml) oral syringes)
EU/2/15/181/003 (5 (1 x 3 ml) oral syringes)
EU/2/15/181/004 (10 (1 x 3 ml) oral syringes)
EU/2/15/181/005 (20 (1 x 3 ml) oral syringes)

15. BATCH NUMBER

Lot {number}

MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS

ORAL SYRINGE

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Sileo



2. QUANTITATIVE PARTICULARS OF THE ACTIVE SUBSTANCES

Dexmedetomidine hydrochloride 0.1 mg/ml

3. BATCH NUMBER

Lot {number}

4. EXPIRY DATE

Exp. {mm/yyyy}

B. PACKAGE LEAFLET

PACKAGE LEAFLET

1. Name of the veterinary medicinal product

Sileo 0.1 mg/ml oromucosal gel for dogs

2. Composition

Each ml of the oromucosal gel contains:

Active substance:

0.1 mg dexmedetomidine hydrochloride equivalent to 0.09 mg dexmedetomidine.

Translucent, green gel.

3. Target species

Dogs.



4. Indications for use

For the alleviation of acute anxiety and fear associated with noise in dogs.

5. Contraindications

Your dog should not be given Sileo if it:

- has severe liver, kidney or heart disease.
- is hypersensitive to the active substance or to any of the excipients.
- is drowsy due to previous medicine.

6. Special warnings

Special precautions for safe use in the target species:

Unlike most other oral veterinary medicinal products, this veterinary medicinal product is not meant to be swallowed. Instead, it must be placed onto the mucosa between the dog's cheek and gum of the dog. Feeding and giving the dog treats within 15 minutes after administration of the gel should therefore be avoided. If the oromucosal gel is swallowed it will become less effective. In case the gel is swallowed the dog can be given another dose if necessary 2 hours after the previous dose.

In extremely nervous, excited or agitated animals the response to the medicine may be reduced.

The safety of administering Sileo to puppies younger than 16 weeks and dogs over 17 years of age has not been studied.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

In case of accidental ingestion or prolonged mucosal contact, seek medical advice immediately and show the package leaflet or the label to the physician. Do not drive as sedation and changes in blood pressure may occur.

Avoid skin, eye or mucosal contact. Wear impermeable disposable gloves when handling the veterinary medicinal product.

In case of accidental spillage onto skin, wash the exposed skin immediately after exposure with large amounts of water and remove contaminated clothes. In case of eye or oromucosal contact, rinse abundantly with fresh water. If symptoms occur, seek the advice of a physician.

People with known hypersensitivity to dexmedetomidine or any of the excipients should avoid contact with the veterinary medicinal product.

Pregnant women should avoid contact with the veterinary medicinal product. Uterine contractions and decreased foetal blood pressure may occur after systemic exposure to dexmedetomidine.

Advice to physicians:

Dexmedetomidine, the active substance of Sileo, is an alpha-2 adrenoceptor agonist. Symptoms after absorption may involve clinical effects including dose-dependent sedation, respiratory depression, bradycardia, hypotension, a dry mouth, and hyperglycaemia. Ventricular arrhythmias have also been reported. Since effects are dose dependent they are more pronounced in small children than adults. Respiratory and haemodynamic symptoms should be treated symptomatically. The specific alpha-2 adrenoceptor antagonist, atipamezole, which is approved for use in animals, has been used in humans but only experimentally to antagonize dexmedetomidine-induced effects.

Information for the veterinary surgeon:

Do not exceed the recommended dose. Signs of sedation may occur when the dose is exceeded. The level and duration of sedation is dose dependent. If sedation occurs, the dog should be kept warm.

Reduced heart rate may be seen after administration of higher than recommended doses of Sileo gel. Blood pressure decreases slightly below normal levels. Respiration rate can occasionally decrease. Higher than recommended doses of Sileo gel may also induce a number of other alpha-2 adrenoceptor mediated effects, which include mydriasis, depression of motor and secretory functions of the gastrointestinal tract, temporary AV-blocks, diuresis and hyperglycaemia. A slight decrease in body temperature may be observed.

The effects of dexmedetomidine can be eliminated using a specific antidote, atipamezole (alpha-2 adrenoceptor antagonist). In case of overdose, the appropriate dose of atipamezole calculated in micrograms is 3 times (3X) the dose of administered dexmedetomidine hydrochloride in Sileo gel. Atipamezole (at the concentration of 5 mg/ml) dose in millilitres is one sixteenth (1/16th) of the dose volume of Sileo gel.

Special precautions for the protection of the environment:

Not applicable.

Pregnancy and lactation:

The safety of the veterinary medicinal product has not been established during pregnancy and lactation. Therefore the use of the veterinary medicinal product during pregnancy and lactation is not recommended.

Interaction with other medicinal products and other forms of interaction:

Inform your veterinary surgeon if your dog is using other medicines.

The use of other central nervous system depressants is expected to potentiate the effects of dexmedetomidine and therefore an appropriate dose adjustment should be made by the veterinary surgeon.

Overdose:

Overdose can cause excessive tiredness. If this occurs the animal should be kept warm.

If an overdose occurs, contact a veterinary surgeon as soon as possible.

The effects of dexmedetomidine can be eliminated using a specific antidote (reversal medicine).

Special restrictions for use and special conditions for use:

Not applicable.

7. Adverse events

Dogs:

Common (1 to 10 animals / 100 animals treated):	Vomiting Tiredness (sedation) Uncontrolled urination Pale mucous membrane ¹
Uncommon (1 to 10 animals / 1 000 animals treated):	Distress Loose stools Swelling around the eyes Drowsiness

¹Transient, observed at the application site due to narrowing of small blood vessels.

Reporting adverse events is important. It allows continuous safety monitoring of a product. If you notice any side effects, even those not already listed in this package leaflet, or you think that the medicine has not worked, please contact, in the first instance, your veterinarian. You can also report any adverse events to the marketing authorisation holder or the local representative of the marketing authorisation holder using the contact details at the end of this leaflet, or via your national reporting system: {national system details}.

8. Dosage for each species, routes and method of administration

Oromucosal gel.

Sileo is administered onto the oral mucosa between the dog's cheek and gum.

The Sileo oral syringe delivers the veterinary medicinal product in small increments (0.25 ml). Each increment is shown as one dot on the plunger. The dosing table provides the number of dots to be administered corresponding to the dog's bodyweight.

The following dosing table provides the dose volume (in dots) to be administered for the corresponding bodyweight. If the dose for the dog is more than 6 dots, half of the dose should be administered to the oral mucosa on one side of the dog's mouth and the other half of the dose onto the other side. Do not exceed the recommended dose.

Bodyweight of dog (kg)	Number of dots
2.0–5.5	1 ●
5.6–12	2 ●●
12.1–20	3 ●●●
20.1–29	4 ●●●●
29.1–39	5 ●●●●●
39.1–50	6 ●●●●●●
50.1–62.5	7 ●●●●●●●
62.6–75.5	8 ●●●●●●●●
75.6–89	9 ●●●●●●●●●

9. Advice on correct administration

Dosing should be performed by an adult. Wear impermeable disposable gloves when handling the veterinary medicinal product.

The first dose should be given as soon as the dog shows the first signs of anxiety, or when the owner detects a typical stimulus (e.g. sound of fireworks or thunder) for eliciting anxiety or fear in the respective dog. Typical signs of anxiety and fear are panting, trembling, pacing (frequent change of place, running around, restlessness), seeking people (clinging, hiding behind, pawing, following), hiding (under furniture, in dark rooms), trying to escape, freezing (absence of movements), refusing to eat food or treats, inappropriate urination, inappropriate defecation, salivation, etc.

If the fear eliciting event continues and the dog shows signs of anxiety and fear again, re-dosing can be done when 2 hours have passed from the previous dose. The veterinary medicinal product can be dosed up to 5 times during each event.

See the detailed instructions and pictures in the end of this leaflet.

10. Withdrawal periods

Not applicable.

11. Special storage precautions

Keep out of the sight and reach of children.

Keep the oral syringe in the outer carton in order to protect from light.

Do not use this veterinary medicinal product after the expiry date which is stated on the oral syringe label and outer carton after “Exp”. The expiry date refers to the last day of that month.

Shelf life after first opening the oral syringe: 4 weeks. Add a note on the carton after “Once opened use by...” to remind you when the 4 weeks have passed.

12. Special precautions for disposal

Medicines should not be disposed of via wastewater or household waste.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any applicable national collection systems. These measures should help to protect the environment.

Ask your veterinary surgeon or pharmacist how to dispose of medicines no longer required.

13. Classification of veterinary medicinal products

Veterinary medicinal product subject to prescription.

14. Marketing authorisation numbers and pack sizes

Marketing authorisation number: EU/2/15/181/001–005

Pack sizes:

- Single pack of 1 oral syringe.
- Multipacks of 3 (3 packs of one oral syringe). Multipacks of 5, 10 and 20 oral syringes are also available but are intended to be supplied only to veterinarians.

Not all pack sizes may be marketed.

15. Date on which the package leaflet was last revised

{DD/MM/YYYY}

Detailed information on this veterinary medicinal product is available in the [Union Product Database \(https://medicines.health.europa.eu/veterinary\)](https://medicines.health.europa.eu/veterinary).

16. Contact details

Marketing authorisation holder:

Orion Corporation
Orionintie 1
FI-02200 Espoo
Finland

Manufacturer responsible for batch release:

Orion Corporation Orion Pharma
Orionintie 1
FI-02200 Espoo
Finland

Local representatives and contact details to report suspected adverse events:

For any information about this veterinary medicinal product, please contact the local representative of the marketing authorisation holder.

België/Belgique/Belgien

V.M.D. n.v.
Hoge Mauw 900
BE-2370 Arendonk
Tél/Tel: +32 (0)14 67 20 51

Lietuva

UAB „Orion Pharma“
Ukmergės g. 126
LT-08100 Vilnius, Lietuva
Tel: +370 5 2769 499

Република България

Orion Corporation
Orionintie 1
FI-02200 Espoo
Tel: + 358 10 4261

Luxembourg/Luxemburg

V.M.D. n.v.
Hoge Mauw 900
2370 Arendonk
Belgique/Belgien
Tél/Tel: +32 (0)14 67 20 51

Česká republika

Orion Pharma s.r.o.
Na Strži 2102/61a,
Praha, 140 00
Tel: +420 227 027 263
orion@orionpharma.cz

Magyarország

Orion Pharma Kft.
1139 Budapest, Pap Károly u. 4-6
Tel.: +36 1 2370603

Danmark

Orion Pharma A/S,
Ørestads Boulevard 73,
2300 København S
Tlf: +45 86 14 00 00

Deutschland

Ecuphar GmbH,
Brandteichstraße 20,
17489 Greifswald,
Deutschland
Tel: +49 (0)3834 83 584 0

Eesti

UAB „Orion Pharma“
Ukmergēs g. 126
LT-08100 Vilnius, Leedu
Tel: +370 5 2769 499

Ελλάδα

ΕΛΑΝΚΟ ΕΛΛΑΣ Α.Ε.Β.Ε.
Λεωφόρος Μεσογείων 335
15231, Χαλάνδρι
Αττική-Ελλάδα
Τηλ.: (+30) 2130065000

España

Ecuphar Veterinaria SLU
C/ Cerdanya, 10-12, planta 6
08173 Sant Cugat del Vallés, Barcelona
Tel: + 34 93 5955000

France

Dômes Pharma FR
57 rue des Bardines
63370 LEMPDES
Tel: +33 (0) 4 73 61 72 27

Hrvatska

Orion Corporation
Orionintie 1
FI-02200 Espoo
Tel: + 358 10 4261

Ireland

Orion Corporation
Orionintie 1
FI-02200 Espoo
Tel: + 358 10 4261

Malta

Orion Corporation
Orionintie 1
FI-02200 Espoo
Tel: + 358 10 4261

Nederland

Ecuphar bv,
Verlengde Poolseweg 16,
4818 CL Breda
Tel: +31 (0)88 003 38 00

Norge

Orion Pharma AS Animal Health
Postboks 4366 Nydalen,
N-0402 Oslo
Tlf: +47 40 00 41 90

Österreich

VetViva Richter GmbH
Durisolstrasse 14
4600 Wels
Austria
Tel.: +43 7242 490 0

Polska

Orion Pharma Poland Sp. z o.o.
ul. Fabryczna 5A,
00-446 Warszawa
Tel: +48 22 833 31 77

Portugal

Belphar LDA
Sintra Business Park, N°7, Edifício 1 -
Escritório 2K
Zona Industrial de Abrunheira
2710-089 Sintra
Tel: + 351 308808321

România

Orion Pharma România srl
B-dul T. Vladimirescu nr 22,
București, 050883-RO
Tel: +40 31845 1646

Slovenija

IRIS d.o.o.
Cesta v Gorice 8
1000 Ljubljana
Tel: +386 (0)1 2006650

Ísland

Orion Corporation
Orionintie 1
FI-02200 Espoo
Tel: + 358 10 4261

Italia

Ecuphar Italia S.R.L.
Viale Francesco Restelli, 3/7
20124 Milano (Italia)
Tel: + 39 0282950604

Κόπος

ΕΛΑΝΚΟ ΕΛΛΑΣ Α.Ε.Β.Ε.
Λεωφόρος Μεσογείων 335
15231, Χαλάνδρι
Αττική-Ελλάδα
Τηλ.: (+30) 2130065000

Latvija

UAB „Orion Pharma“
Ukmergės g. 126
LT-08100 Vilnius, Lietuva
Tel: +370 5 2769 499

Slovenská republika

Orion Pharma s.r.o.
Na strži 2102/61a,
Praha, 140 00, ČR
Tel: +420 227 027 263
orion@orionpharma.sk

Suomi/Finland


ORION PHARMA Eläinlääkkeet
PL/PB 425,
FI-20101 Turku/Åbo
Puh/Tel: +358 10 4261


Sverige

Orion Pharma AB, Animal Health,
Golfvägen 2,
SE-182 31 Danderyd
Tel: +46 8 623 64 40





United Kingdom (Northern Ireland)

Orion Corporation
Orionintie 1
FI-02200 Espoo
Tel: + 358 10 4261

17. Other information**INSTRUCTIONS FOR DOSING THE GEL:****PREPARATIONS FOR DOSING:**



DOSE SELECTION AND DOSING:



1. WEAR GLOVES

Wear impermeable disposable gloves when handling the veterinary medicinal product and handling the oral syringe.

2. HOLD PLUNGER

Hold the oral syringe plunger so that you can see the dot markings.

3. ROTATE RING

Hold the plunger and rotate the ring towards the barrel to select the dose your veterinarian has prescribed to your dog. **Do not pull the plunger!**

4. SET THE DOSE


Position the dosing ring so that the side nearest the barrel is in line with the graduation mark (black line), and the required number of dots shows between the dosing ring and the barrel.

5. CONFIRM THE DOSE

Make sure that you count the dots from the correct part of the plunger (shown in yellow) and that the ring is in line with the graduation mark (shown with the yellow arrow).

6. FOLLOWING DOSES

To administer following doses from the same syringe: Repeat the previous “Set the dose” and “Confirm the dose” parts of the instructions.




7. PULL CAP (TIGHT)

Pull the cap strongly while holding the barrel. **Note** the cap is very tight (pull, do not twist). Save the cap for replacement.




8. DOSE INTO CHEEK

Place the oral syringe tip between the dog's cheek and gum and press the plunger until the dosing ring causes the plunger to stop.



9. NOT SWALLOWED

IMPORTANT: The gel should not be swallowed. If the gel is swallowed, it may not be effective.



10. BACK TO PACKAGE

Recap the oral syringe and return it to the outer package as the veterinary medicinal product is sensitive to light. Make sure that the carton is closed properly. Keep the package out of sight and reach of children at all times. Remove and discard gloves.